TODAY'S CHALLENGES - TREATMENT OF ANEMIA IN PATIENTS WITH RENAL FAILURE IN COVID-19 CIRCUMSTANCES
Abstract
A high rate of severe anemia wasobserved in patients with acute kidney injury (AKI) and also in patients on dialysis or chronic kidney disease (CKD) who contracted anew infectious disease caused by SARS-CoV-2. The most severe anemia in COVID-19 occurs in people with severe systemic inflammation, which may occur during illness. Recent studies showed that elevated concentrations of D-dimer are associated with lower hemoglobin and higher serum ferritin. A controversial aspect of therapy in patients with kidney diseases and COVID-19 infection is observed in both populations (with AKI or CKD) about the use of erythropoiesis-stimulating agents (ESA) for the treatment of anemia.
Erythropoiesis stimulating agents represent a revolution in the treatment of anemia in patients with kidney disease. But, he combined interaction of the inflammatory and immune systems with the coagulation system is extremely pronounced in patients with COVID-19 infection. The question is how to treat anemia in patients with COVID-19, whether ESAs are potentially harmful or beneficial, what encourages us to continue the treatment of anemia in patients with COVID-19 usingESA and what are the possibilities to reduce or exceed the risks, as well as whether this therapeutic approach is a new challenge in the treatment of Covid-19 infection.
References
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will country-based mitigation measures influence the course of the COVID-19 epidemic? Lancet 2020;395:931-4. [CrossRef] [PubMed]
Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA 2020;323:1406-7. [CrossRef] [PubMed]
Cantarelli C, Angeletti A, Cravedi P. Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity. Am J Transplant 2019;19(9): 2407-14. [CrossRef] [PubMed]
Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in haemodia-lysis patients. Hemodial Int 2009;13:222-34. [CrossRef] [PubMed]
Chen N, Hao C, Liu B-C, Lin H, Wang C, Xing C, et al. Roxadustat treatment for anemia in patients under-going long-term dialysis. N Engl J Med 2019;381(11): 1011-22. [CrossRef] [PubMed]
Chu KH, Tsang WK, Tang CS, Lam MF, Lai FM, To KF, et al. Acute renal impairment in coronavirus-associa-ted severe acute respiratory syndrome. Kidney Int 2005;67:698-705. [CrossRef] [PubMed]
Drakesmith H, Prentice A. Viral infection and iron metabolism. Nat Rev Microbiol 2008;6(7):541-52. [CrossRef] [PubMed]
Fishbane S, Hirsch JS. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19. Am J Kidney Dis 2020;76(3):303-5. [CrossRef] [PubMed]
French C. Erythropoietin in Critical Illness and Trauma. Crit Care Clin 2019;35(2):277-87. [CrossRef] [PubMed]
Ganz T. Iron and infection. Int J Hematol 2018; 107(1):7-15. [CrossRef] [PubMed]
Hadadi A, Mortezazadeh M, Kolahdouzan K, Alavian G. Does recombinant human erythropoietin administra-tion in critically ill COVID-19 patients have miraculous therapeutic effects? J Med Virol 2020;92(7):915-18. [CrossRef] [PubMed]
He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and trans-missibility of COVID-19. Nat Med 2020;26(5):672-5. [CrossRef] [PubMed]
Heitrich M, Garcia DM, Stoyanoff TR, Rodriguez JP, Todaro JS, Aguirre MV. Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation. Biomed Pharmacother 2016;82:606-13. [CrossRef] [PubMed]
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombo-sis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089-98. [CrossRef] [PubMed]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395:497-506. [CrossRef] [PubMed]
Ingraham NE, Lotfi-Emran S, Thielen BK, Techar K, Morris RS, Holtan SG, et al. Immunomodulation in Covid-19. Lancet Respir Med 2020;8(6):544-6. [CrossRef] [PubMed]
Ito T, Hamazaki Y, Takaori-Kondo A, Minato N. Bone Marrow Endothelial Cells Induce Immature and Mature B Cell Egress in Response to Erythropoietin. Cell Struct Funct 2017;42(2):149-57. [CrossRef] [PubMed]
Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, et al. Acute Pulmonary Embo-lism in Patients with COVID-19 at CT Angiography and Relationship to D-Dimer Levels. Radiology 2020; 296(3):E189-E191. [CrossRef] [PubMed]
Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science 2020;368:489-93. [CrossRef] [PubMed]
Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on Kidney Dysfunctions of COVID-19 Patients. MedRxiv 2020. [CrossRef]
Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, et al. Failure of anticoagulant thrombo-prophylaxis: risk factors in medical-surgical critically ill patients. Crit Care Med 2015;43:401-10. [CrossRef] [PubMed]
MacRedmond R, Singhera GK, Dorscheid DR. Erythro-poietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury. Eur Respir J 2009;33: 1403-14. [CrossRef] [PubMed]
Nekoui A, Blaise G. Erythropoietin and Nonhemato-poietic Effects. Am J Med Sci 2017;353(1):76-81. [CrossRef] [PubMed]
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythro-poiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010;153:23-33. [CrossRef] [PubMed]
Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis 2020;20:410-11. [CrossRef] [PubMed]
Pfeffer MA, Burdmann EA, Chen C-Y, Cooper ME, de Zeeuw D, Eckardt K-U, et al. A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. N Engl J Med 2009;361(21):2019-32. [CrossRef] [PubMed]
Qian G, Yang N, Yan Ma AH, Wang L, Li G, Chen X, et al. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China. Clin Infect Dis 2020;71(15):861-2. [CrossRef] [PubMed]
Song JY, Yun JG, Noh JY, Cheong HJ, Kim WJ. Covid-19 in South Korea - Challenges of Subclinical Manifestations. N Engl J Med 2020;382:1858-9. [CrossRef] [PubMed]
Stoyanoff TR, Rodriguez JP, Todaro JS, Colavita JPM, Torres AM, Aguirre MV. Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury. Biomed Pharmacother 2018;107:1046-55. [CrossRef] [PubMed]
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9. [CrossRef] [PubMed]
Wang H. Maintenance Hemodialysis and COVID-19: Saving Lives With Caution, Care, and Courage. Kidney Med 2020;2(3):365-6. [CrossRef] [PubMed]
WE Wei, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. Morb Mortal Wkly Rep 2020;69:411-15. [CrossRef] [PubMed]
Weiss G, Ganz T, Goodnough LT. Anemia of inflame-mation. Blood 2019;133(1):40-50. [CrossRef] [PubMed]
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). 2020 Feb ”cited 2020 Mar 02”. Available from: URL: https://www.who.int/docs/default-source/ coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
Ye F, Xu S, Rong Z, Xu R, Liu X, Deng P, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis 2020;94:133-8. [CrossRef] [PubMed]
Zhang GX, Du YJ, Li XH, Feng ZT, Zhao H, Sun Y, et al. Protective effect of erythropoietin against lipopoly-saccharide induced inflammation and mitochondrial damage in liver. J Biol Regul Homeost Agents 2018; 32(2):199-206. [PubMed]
Zhang X, Dong S, Qin Y, Bian X. Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms. Mol Med Rep 2015;11(5):3317-29. [CrossRef] [PubMed]
Zhang X, Dong S. Protective Effects of Erythropoietin towards Acute Lung Injuries in Rats with Sepsis and Its Related Mechanisms. Ann Clin Lab Sci 2019;49(2): 257-64. [PubMed]
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. [CrossRef] [PubMed]